{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:09:26Z","timestamp":1763464166808,"version":"3.45.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009609","name":"Hospital Infantil de M\u00e9xico Federico G\u00f3mez","doi-asserted-by":"publisher","award":["HIM-2021-007 SSA 1696"],"award-info":[{"award-number":["HIM-2021-007 SSA 1696"]}],"id":[{"id":"10.13039\/501100009609","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Innovaci\u00f3n","award":["CF-2023-G-93"],"award-info":[{"award-number":["CF-2023-G-93"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serological evaluation plays a crucial role in understanding cross-reactivity, the prevalence of infection, immune response in COVID-19 disease, asymptomatic infections, and vaccine effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Recombinant spike (rS) and Nucleocapsid (rN) proteins from SARS-CoV-2 were used to determine IgG antibodies (Abs) in serum samples obtained from Mexican adults and paediatrics before and during the pandemic by enzyme-linked immunosorbent assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Human sera from 2003 to 2016 showed higher levels of cross seropositivity (54.5\u201275%) against rS and rN. In serum samples from adult patients with COVID-19, the reactivity intensity (RI) depended on the severity of the disease, whereas in convalescent paediatric patients with COVID-19, SARS-CoV-2 viral load depended on sex and comorbidities. Regarding vaccine effectiveness monitoring, an increased RI of anti-rS IgG was observed in people vaccinated against COVID-19 who had a natural infection with SARS-CoV-2. During the vaccination scheme, an increase in IgG Abs level was observed with the second dose, whereas a decrease was observed after six months of vaccination. Vaccine boosters increased RI in either homologous\/heterologous administration of mRNA and non-replicating viral vector vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Epidemiological outbreaks and the circulation of non-SARS-CoV-2 coronaviruses may contribute to the primary causes of the observed cross-reactions in antibodies. Furthermore, factors such as viral load and disease severity in infected patients, prior illnesses, the dosage of vaccine and booster shots, and the type of vaccine used in COVID-19-vaccinated individuals may also influence the increase in IgG antibodies. Assessing the antibody-based humoral immune response in serum samples collected before and during an outbreak or pandemic could aid in comprehending emerging and re-emerging diseases and developing effective preventive strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12038-3","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:15:40Z","timestamp":1763460940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross-reactivity IgG, viral load, severity and vaccination outcome as an approach for understanding humoral immune response against SARS-CoV-2"],"prefix":"10.1186","volume":"25","author":[{"given":"Jesus","family":"Contreras-Villa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Griselda","family":"Rodr\u00edguez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel","family":"Parra-Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Romo-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Cort\u00e9s-Sarabia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeus","family":"Salda\u00f1a-Ahuactzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Flores-Alanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Aureoles-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Salazar-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Eslava-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulises","family":"Hern\u00e1ndez-Chi\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Cruz-Rangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Morales-Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Eugenio","family":"Cancino-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor M.","family":"Luna-Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"12038_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181\u201392.","journal-title":"Nat Rev Microbiol"},{"key":"12038_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","volume":"66","author":"PS Masters","year":"2006","unstructured":"Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193\u2013292.","journal-title":"Adv Virus Res"},{"key":"12038_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-0900-2_1","volume":"2203","author":"Y Wang","year":"2020","unstructured":"Wang Y, Grunewald M, Perlman S. Coronaviruses: an updated overview of their replication and pathogenesis. Methods Mol Biol. 2020;2203:1\u201329.","journal-title":"Methods Mol Biol"},{"key":"12038_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4102\/ojvr.v88i1.1872","volume":"88","author":"EN Mulabbi","year":"2021","unstructured":"Mulabbi EN, Tweyongyere R, Byarugaba DK. The history of the emergence and transmission of human coronaviruses. Onderstepoort J Vet Res. 2021;88:e1\u20138.","journal-title":"Onderstepoort J Vet Res"},{"key":"12038_CR5","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa030781","volume":"348","author":"TG Ksiazek","year":"2003","unstructured":"Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953\u201366.","journal-title":"N Engl J Med"},{"key":"12038_CR6","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814\u201320.","journal-title":"N Engl J Med"},{"key":"12038_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727\u201333.","journal-title":"N Engl J Med"},{"key":"12038_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/vaccines8020309","volume":"8","author":"C Conte","year":"2020","unstructured":"Conte C, Sogni F, Affanni P, Veronesi L, Argentiero A, Esposito S. Vaccines against coronaviruses: the state of the Art. Vaccines (Basel). 2020;8:309.","journal-title":"Vaccines (Basel)"},{"key":"12038_CR9","doi-asserted-by":"publisher","first-page":"e14383","DOI":"10.1111\/cbdd.14383","volume":"103","author":"V Saravanan","year":"2024","unstructured":"Saravanan V, Chagaleti BK, Narayanan PL, Anandan VB, Manoharan H, Anjana GV, et al. Discovery and development of COVID-19 vaccine from laboratory to clinic. Chem Biol Drug Des. 2024;103:e14383.","journal-title":"Chem Biol Drug Des"},{"key":"12038_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u2013e2808.","journal-title":"Cell"},{"key":"12038_CR11","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1016\/j.cell.2023.06.005","volume":"186","author":"J Baggen","year":"2023","unstructured":"Baggen J, Jacquemyn M, Persoons L, Vanstreels E, Pye VE, Wrobel AG, et al. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. Cell. 2023;186:3427\u2013e344222.","journal-title":"Cell"},{"key":"12038_CR12","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1128\/JVI.77.5.2922-2927.2003","volume":"77","author":"K Narayanan","year":"2003","unstructured":"Narayanan K, Chen C-J, Maeda J, Makino S. Nucleocapsid-independent specific viral RNA packaging via viral envelope protein and viral RNA signal. J Virol. 2003;77:2922\u20137.","journal-title":"J Virol"},{"key":"12038_CR13","doi-asserted-by":"publisher","first-page":"761173","DOI":"10.3389\/fmolb.2022.761173","volume":"9","author":"B Zhang","year":"2022","unstructured":"Zhang B, Tian J, Zhang Q, Xie Y, Wang K, Qiu S, et al. Comparing the nucleocapsid proteins of human coronaviruses: Structure, Immunoregulation, Vaccine, and targeted drug. Front Mol Biosci. 2022;9:761173.","journal-title":"Front Mol Biosci"},{"key":"12038_CR14","doi-asserted-by":"publisher","first-page":"2191577","DOI":"10.1080\/21645515.2023.2191577","volume":"19","author":"T Yadav","year":"2023","unstructured":"Yadav T, Kumar S, Mishra G, Saxena SK. Tracking the COVID-19 vaccines: the global landscape. Hum Vaccin Immunother. 2023;19:2191577.","journal-title":"Hum Vaccin Immunother"},{"key":"12038_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/08830185.2022.2079642","volume":"42","author":"W Gong","year":"2023","unstructured":"Gong W, Parkkila S, Wu X, Aspatwar A. SARS-CoV-2 variants and COVID-19 vaccines: current challenges and future strategies. Int Rev Immunol. 2023;42:393\u2013414.","journal-title":"Int Rev Immunol"},{"key":"12038_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","volume":"20","author":"B Zeng","year":"2022","unstructured":"Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20:200.","journal-title":"BMC Med"},{"key":"12038_CR17","doi-asserted-by":"crossref","unstructured":"None JLXH, W YY, Z XL. Y Z, Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control. 2021;49.","DOI":"10.1016\/j.ajic.2020.06.008"},{"key":"12038_CR18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1080\/22221751.2021.1905488","volume":"10","author":"L Guo","year":"2021","unstructured":"Guo L, Wang Y, Kang L, Hu Y, Wang L, Zhong J, et al. Cross-reactive antibody against human coronavirus OC43 Spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021;10:664\u201376.","journal-title":"Emerg Microbes Infect"},{"key":"12038_CR19","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/infdis\/jiab333","volume":"224","author":"K Shrwani","year":"2021","unstructured":"Shrwani K, Sharma R, Krishnan M, Jones T, Mayora-Neto M, Cantoni D, et al. Detection of serum Cross-Reactive antibodies and memory response to SARS-CoV-2 in prepandemic and Post-COVID-19 convalescent samples. J Infect Dis. 2021;224:1305\u201315.","journal-title":"J Infect Dis"},{"key":"12038_CR20","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.immuni.2021.05.001","volume":"54","author":"HL Dugan","year":"2021","unstructured":"Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity. 2021;54:1290\u2013e13037.","journal-title":"Immunity"},{"key":"12038_CR21","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.3390\/v13112325","volume":"13","author":"R Borrega","year":"2021","unstructured":"Borrega R, Nelson DKS, Koval AP, Bond NG, Heinrich ML, Rowland MM, et al. Cross-Reactive antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 blood samples from Sierra Leoneans. Viruses. 2021;13:2325.","journal-title":"Viruses"},{"key":"12038_CR22","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.3390\/v14102162","volume":"14","author":"A Flores-Alanis","year":"2022","unstructured":"Flores-Alanis A, Salda\u00f1a-Ahuactzi Z, Parra-Ortega I, L\u00f3pez-Ram\u00edrez P, Salazar-Garc\u00eda M, Alem\u00e1n-Garc\u00eda YP, et al. Clinical characteristics of coronavirus disease (COVID-19) in Mexican children and adolescents. Viruses. 2022;14:2162.","journal-title":"Viruses"},{"key":"12038_CR23","doi-asserted-by":"publisher","first-page":"e0273097","DOI":"10.1371\/journal.pone.0273097","volume":"17","author":"K Cort\u00e9s-Sarabia","year":"2022","unstructured":"Cort\u00e9s-Sarabia K, Cruz-Rangel A, Flores-Alanis A, Salazar-Garc\u00eda M, Jim\u00e9nez-Garc\u00eda S, Rodr\u00edguez-Mart\u00ednez G, et al. Clinical features and severe acute respiratory syndrome-coronavirus-2 structural protein-based serology of Mexican children and adolescents with coronavirus disease 2019. PLoS ONE. 2022;17:e0273097.","journal-title":"PLoS ONE"},{"key":"12038_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0921-4488(98)00093-5","volume":"30","author":"GG Perrin","year":"1998","unstructured":"Perrin GG, Benoit C, Saunders M. Influence of storage and heating on Sera in detection of CAEV antibodies. Small Ruminant Res. 1998;30:153\u20135.","journal-title":"Small Ruminant Res"},{"key":"12038_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.11613\/BM.2013.009","volume":"23","author":"S Cuhadar","year":"2013","unstructured":"Cuhadar S, Koseoglu M, Atay A, Dirican A. The effect of storage time and freeze-thaw cycles on the stability of serum samples. Biochem Med (Zagreb). 2013;23:70\u20137.","journal-title":"Biochem Med (Zagreb)"},{"key":"12038_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","volume":"221","author":"A Frey","year":"1998","unstructured":"Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1998;221:35\u201341.","journal-title":"J Immunol Methods"},{"key":"12038_CR27","doi-asserted-by":"publisher","first-page":"e2282","DOI":"10.1002\/rmv.2282","volume":"32","author":"MM Kesheh","year":"2022","unstructured":"Kesheh MM, Hosseini P, Soltani S, Zandi M. An overview on the seven pathogenic human coronaviruses. Rev Med Virol. 2022;32:e2282.","journal-title":"Rev Med Virol"},{"key":"12038_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41392-020-0190-2","volume":"5","author":"B Chen","year":"2020","unstructured":"Chen B, Tian E-K, He B, Tian L, Han R, Wang S, et al. Overview of lethal human coronaviruses. Signal Transduct Target Ther. 2020;5:89.","journal-title":"Signal Transduct Target Ther"},{"key":"12038_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pbiomolbio.2020.10.006","volume":"161","author":"L Guruprasad","year":"2021","unstructured":"Guruprasad L. Human coronavirus Spike protein-host receptor recognition. Prog Biophys Mol Biol. 2021;161:39\u201353.","journal-title":"Prog Biophys Mol Biol"},{"key":"12038_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","volume":"27","author":"A Grifoni","year":"2020","unstructured":"Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27:671\u2013e6802.","journal-title":"Cell Host Microbe"},{"key":"12038_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ijid.2020.10.104","volume":"102","author":"FY Tso","year":"2021","unstructured":"Tso FY, Lidenge SJ, Pe\u00f1a PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021;102:577\u201383.","journal-title":"Int J Infect Dis"},{"key":"12038_CR32","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3390\/microorganisms8121993","volume":"8","author":"ER Simula","year":"2020","unstructured":"Simula ER, Manca MA, Jasemi S, Uzzau S, Rubino S, Manchia P, et al. HCoV-NL63 and SARS-CoV-2 share recognized epitopes by the humoral response in Sera of people collected Pre- and during CoV-2 pandemic. Microorganisms. 2020;8:1993.","journal-title":"Microorganisms"},{"key":"12038_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol. 2023;23:189\u201399.","journal-title":"Nat Rev Immunol"},{"key":"12038_CR34","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/j.ijid.2013.01.006","volume":"17","author":"A Galindo-Fraga","year":"2013","unstructured":"Galindo-Fraga A, Ortiz-Hern\u00e1ndez AA, Ram\u00edrez-Venegas A, V\u00e1zquez RV, Moreno-Espinosa S, Llamosas-Gallardo B, et al. Clinical characteristics and outcomes of influenza and other influenza-like illnesses in Mexico City. Int J Infect Dis. 2013;17:e510\u2013517.","journal-title":"Int J Infect Dis"},{"key":"12038_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jcv.2007.08.007","volume":"40","author":"X Shao","year":"2007","unstructured":"Shao X, Guo X, Esper F, Weibel C, Kahn JS. Seroepidemiology of group I human coronaviruses in children. J Clin Virol. 2007;40:207\u201313.","journal-title":"J Clin Virol"},{"key":"12038_CR36","doi-asserted-by":"publisher","first-page":"e0176298","DOI":"10.1371\/journal.pone.0176298","volume":"12","author":"L Fernandes-Matano","year":"2017","unstructured":"Fernandes-Matano L, Monroy-Mu\u00f1oz IE, Angeles-Mart\u00ednez J, Sarquiz-Martinez B, Palomec-Nava ID, Pardav\u00e9-Alejandre HD, et al. Prevalence of non-influenza respiratory viruses in acute respiratory infection cases in Mexico. PLoS ONE. 2017;12:e0176298.","journal-title":"PLoS ONE"},{"key":"12038_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijid.2017.06.020","volume":"62","author":"RM Wong-Chew","year":"2017","unstructured":"Wong-Chew RM, Garc\u00eda-Le\u00f3n ML, Noyola DE, Perez Gonzalez LF, Gaitan Meza J, Vilase\u00f1or-Sierra A, et al. Respiratory viruses detected in Mexican children younger than 5 years old with community-acquired pneumonia: a National multicenter study. Int J Infect Dis. 2017;62:32\u20138.","journal-title":"Int J Infect Dis"},{"key":"12038_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jcv.2018.01.019","volume":"101","author":"ME Killerby","year":"2018","unstructured":"Killerby ME, Biggs HM, Haynes A, Dahl RM, Mustaquim D, Gerber SI, et al. Human coronavirus circulation in the united States 2014\u20132017. J Clin Virol. 2018;101:52\u20136.","journal-title":"J Clin Virol"},{"key":"12038_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/all.15593","volume":"78","author":"H-P Zhang","year":"2023","unstructured":"Zhang H-P, Sun Y-L, Wang Y-F, Yazici D, Azkur D, Ogulur I, et al. Recent developments in the immunopathology of COVID-19. Allergy. 2023;78:369\u201388.","journal-title":"Allergy"},{"key":"12038_CR40","first-page":"803","volume":"15","author":"M Jafari","year":"2023","unstructured":"Jafari M, Asli S, Moghbeli F, Fesharaki MG, Hajiahmadi N, Mojtahedzadeh F, et al. Persistence of SARS-CoV-2-antibodies against N, S and RBD after natural infection. Iran J Microbiol. 2023;15:803\u201310.","journal-title":"Iran J Microbiol"},{"key":"12038_CR41","doi-asserted-by":"publisher","first-page":"eabd4250","DOI":"10.1126\/science.abd4250","volume":"370","author":"E Shrock","year":"2020","unstructured":"Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370:eabd4250.","journal-title":"Science"},{"key":"12038_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.pulmoe.2021.03.008","volume":"27","author":"JL Boechat","year":"2021","unstructured":"Boechat JL, Chora I, Morais A, Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology \u2013 Current perspectives. Pulmonology. 2021;27:423\u201337.","journal-title":"Pulmonology"},{"key":"12038_CR43","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3390\/ijms23031716","volume":"23","author":"E Gusev","year":"2022","unstructured":"Gusev E, Sarapultsev A, Solomatina L, Chereshnev V. SARS-CoV-2-Specific immune response and the pathogenesis of COVID-19. IJMS. 2022;23:1716.","journal-title":"IJMS"},{"key":"12038_CR44","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5:1185\u201391.","journal-title":"Nat Microbiol"},{"key":"12038_CR45","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/microorganisms11041015","volume":"11","author":"EE Nakayama","year":"2023","unstructured":"Nakayama EE, Shioda T. SARS-CoV-2 related Antibody-Dependent enhancement phenomena in vitro and in vivo. Microorganisms. 2023;11:1015.","journal-title":"Microorganisms"},{"key":"12038_CR46","first-page":"147","volume":"21","author":"O Puhach","year":"2023","unstructured":"Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat Rev Microbiol. 2023;21:147\u201361.","journal-title":"Nat Rev Microbiol"},{"key":"12038_CR47","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41564-022-01105-z","volume":"7","author":"R Ke","year":"2022","unstructured":"Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat Microbiol. 2022;7:640\u201352.","journal-title":"Nat Microbiol"},{"key":"12038_CR48","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996\u2013e101219.","journal-title":"Cell"},{"key":"12038_CR49","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.molcel.2023.11.032","volume":"84","author":"H Zhao","year":"2024","unstructured":"Zhao H, Cai Z, Rao J, Wu D, Ji L, Ye R, et al. SARS-CoV-2 RNA stabilizes host mRNAs to elicit Immunopathogenesis. Mol Cell. 2024;84:490\u2013e5059.","journal-title":"Mol Cell"},{"key":"12038_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. 2021;21:181\u201392.","journal-title":"Lancet Infect Dis"},{"key":"12038_CR51","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet. 2021;396:1979\u201393.","journal-title":"Lancet"},{"key":"12038_CR52","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"12038_CR53","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671\u201381.","journal-title":"Lancet"},{"key":"12038_CR54","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"12038_CR55","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1\u20132 trial of a SARS-CoV-2 Recombinant Spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320\u201332.","journal-title":"N Engl J Med"},{"key":"12038_CR56","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384:1824\u201335.","journal-title":"N Engl J Med"},{"key":"12038_CR57","doi-asserted-by":"publisher","first-page":"1437267","DOI":"10.3389\/fimmu.2024.1437267","volume":"15","author":"S Bai","year":"2024","unstructured":"Bai S, Zhou S, Zhang J, Chen W, Lv M, Wang J, et al. Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent Pneumococcal polysaccharide vaccine in adults aged\u2009\u2265\u200960 years: a phase 4, randomized, open-label study. Front Immunol. 2024;15:1437267.","journal-title":"Front Immunol"},{"key":"12038_CR58","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","volume":"185","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, G\u00e1lvez RI, et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185:2434\u2013e245117.","journal-title":"Cell"},{"key":"12038_CR59","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","volume":"185","author":"K R\u00f6ltgen","year":"2022","unstructured":"R\u00f6ltgen K, Nielsen SCA, Silva O, Younes SF, Zaslavsky M, Costales C, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185:1025\u2013e104014.","journal-title":"Cell"},{"key":"12038_CR60","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s15010-021-01751-1","volume":"50","author":"O Uzun","year":"2022","unstructured":"Uzun O, Akpolat T, Varol A, Turan S, Bektas SG, Cetinkaya PD, et al. COVID-19: vaccination vs. hospitalization. Infection. 2022;50:747\u201352.","journal-title":"Infection"},{"key":"12038_CR61","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","volume":"400","author":"U Agrawal","year":"2022","unstructured":"Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of National prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022;400:1305\u201320.","journal-title":"Lancet"},{"key":"12038_CR62","doi-asserted-by":"crossref","unstructured":"Permpikul P, Tongyoo S, Chaimayo C, Kanpai P, Virat J, Virat S, et al. Anti-SARS-CoV-2 antibody among SARS-CoV-2 vaccinated vs post-infected blood donors in a tertiary hospital, Bangkok, Thailand. PLoS One. 2023;18:e0285737.","DOI":"10.1371\/journal.pone.0285737"},{"key":"12038_CR63","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/vaccines9090999","volume":"9","author":"O Guzm\u00e1n-Mart\u00ednez","year":"2021","unstructured":"Guzm\u00e1n-Mart\u00ednez O, Guardado K, de Guevara EL, Navarro S, Hern\u00e1ndez C, Zenteno-Cuevas R, et al. IgG antibodies generation and side effects caused by Ad5-nCoV vaccine (CanSino Biologics) and BNT162b2 vaccine (Pfizer\/BioNTech) among Mexican population. Vaccines. 2021;9:999.","journal-title":"Vaccines"},{"key":"12038_CR64","doi-asserted-by":"publisher","first-page":"17966","DOI":"10.1038\/s41598-022-22921-7","volume":"12","author":"JA Cruz-Cardenas","year":"2022","unstructured":"Cruz-Cardenas JA, Gutierrez M, L\u00f3pez-Arredondo A, Casta\u00f1eda-Delgado JE, Rojas-Martinez A, Nakamura Y, et al. A pseudovirus-based platform to measure neutralizing antibodies in Mexico using SARS-CoV-2 as proof-of-concept. Sci Rep. 2022;12:17966.","journal-title":"Sci Rep"},{"key":"12038_CR65","doi-asserted-by":"publisher","first-page":"e0237622","DOI":"10.1128\/spectrum.02376-22","volume":"11","author":"L Fernandes-Matano","year":"2023","unstructured":"Fernandes-Matano L, Salas-Lais AG, Grajales-Mu\u00f1iz C, Hern\u00e1ndez-\u00c1vila M, Garfias-Becerra YO, Rodr\u00edguez-Sep\u00falveda MC, et al. Longevity and neutralizing capacity of IgG antibodies against SARS-CoV-2 generated by the application of BNT162b2, AZD1222, Convidecia, sputnik V, and coronavac vaccines: a cohort study in the Mexican population. Microbiol Spectr. 2023;11:e0237622.","journal-title":"Microbiol Spectr"},{"key":"12038_CR66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.imlet.2022.10.002","volume":"251\u2013252","author":"JJ Morales-N\u00fa\u00f1ez","year":"2022","unstructured":"Morales-N\u00fa\u00f1ez JJ, Mu\u00f1oz-Valle JF, Machado-Sulbar\u00e1n AC, D\u00edaz-P\u00e9rez SA, Torres-Hern\u00e1ndez PC, Panduro-Espinoza BV, et al. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: reactogenicity and neutralizing antibodies. Immunol Lett. 2022;251\u2013252:20\u20138.","journal-title":"Immunol Lett"},{"key":"12038_CR67","doi-asserted-by":"publisher","first-page":"1403784","DOI":"10.3389\/fimmu.2024.1403784","volume":"15","author":"A Garza-Silva","year":"2024","unstructured":"Garza-Silva A, Rivera-Salinas D, Rivera-Cavazos A, Fern\u00e1ndez-Chau IF, Cepeda-Medina AB, Morales-Rodr\u00edguez DP, et al. Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina. Front Immunol. 2024;15:1403784.","journal-title":"Front Immunol"},{"key":"12038_CR68","doi-asserted-by":"crossref","unstructured":"Fernandes-Matano L, Salas-Lais AG, Grajales-Mu\u00f1iz C, Hern\u00e1ndez-\u00c1vila M, Garfias-Becerra YO, Rodr\u00edguez-Sep\u00falveda MC, et al. Longevity and neutralizing capacity of IgG antibodies against SARS-CoV-2 generated by the application of BNT162b2, AZD1222, Convidecia, sputnik V, and coronavac vaccines: a cohort study in the Mexican population. Microbiol Spectr. 2023;11:e02376\u201322.","DOI":"10.1128\/spectrum.02376-22"},{"key":"12038_CR69","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","volume":"9","author":"D Hillus","year":"2021","unstructured":"Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021;9:1255\u201365.","journal-title":"Lancet Respir Med"},{"key":"12038_CR70","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/vaccines9080857","volume":"9","author":"L Benning","year":"2021","unstructured":"Benning L, T\u00f6llner M, Hidmark A, Schaier M, Nusshag C, K\u00e4lble F, et al. Heterologous ChAdOx1 nCoV-19\/BNT162b2 Prime-Boost vaccination induces strong humoral responses among health care workers. Vaccines (Basel). 2021;9:857.","journal-title":"Vaccines (Basel)"},{"key":"12038_CR71","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374:abm0829.","journal-title":"Science"},{"key":"12038_CR72","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1126\/science.abg9175","volume":"372","author":"L Stamatatos","year":"2021","unstructured":"Stamatatos L, Czartoski J, Wan Y-H, Homad LJ, Rubin V, Glantz H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;372:1413\u20138.","journal-title":"Science"},{"key":"12038_CR73","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","volume":"591","author":"C Gaebler","year":"2021","unstructured":"Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639\u201344.","journal-title":"Nature"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12038-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:04:58Z","timestamp":1763463898000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-12038-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12038"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12038-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was reviewed and approved by the Research Committee, Ethics Committee, and Biosecurity Committee from HIMFG with grant numbers HIM-2021-007 SSA 1696 (Adults) and HIM-2020-029 SSA-1664 (children and adolescents). The work was carried out following the international guidelines of the Helsinki postulates. Blood samples were collected according to the ethics and biosafety protocols published in the laboratory\u2019s standardised guidelines. Since the general health law regulations on research state that sampling by either middle finger puncture or venipuncture is considered a minimal-risk procedure. All volunteers in the study provided informed consent (adults) and settlement (children and adolescents), which the corresponding author (V.L.) can provide upon request. All data were anonymised before analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1606"}}